Literature DB >> 24900786

Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design.

Yanlong Zhao1, Xi Zhang2, Yingyi Chen1, Shaoyong Lu1, Yuefeng Peng3, Xiang Wang2, Chengliang Guo2, Aiwu Zhou1, Jingmiao Zhang1, Yu Luo1, QianCheng Shen1, Jian Ding2, Linghua Meng2, Jian Zhang1.   

Abstract

The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival. Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy. We determined the crystal structure of the human PI3Kα-PI103 complex to unravel molecular interactions. Based on the structure, substitution at the R1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site. Interestingly, the crystal structure of the PI3Kα-9d complex revealed that the flexibility of Lys802 can also induce additional space at the catalytic site for further modification. Thus, these crystal structures provide a molecular basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3Kα inhibitors.

Entities:  

Keywords:  PI103; PI3K; cancer therapy; crystal structure; drug design

Year:  2013        PMID: 24900786      PMCID: PMC4027628          DOI: 10.1021/ml400378e

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

Review 1.  Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.

Authors:  John G Foster; Matthew D Blunt; Edward Carter; Stephen G Ward
Journal:  Pharmacol Rev       Date:  2012-10       Impact factor: 25.468

Review 2.  The role of the PI3K-AKT pathway in melanoma.

Authors:  Michael A Davies
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

3.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Authors:  Qi-Wen Fan; Zachary A Knight; David D Goldenberg; Wei Yu; Keith E Mostov; David Stokoe; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

4.  Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

Authors:  Montserrat Camps; Thomas Rückle; Hong Ji; Vittoria Ardissone; Felix Rintelen; Jeffrey Shaw; Chiara Ferrandi; Christian Chabert; Corine Gillieron; Bernard Françon; Thierry Martin; Denise Gretener; Dominique Perrin; Didier Leroy; Pierre-Alain Vitte; Emilio Hirsch; Matthias P Wymann; Rocco Cirillo; Matthias K Schwarz; Christian Rommel
Journal:  Nat Med       Date:  2005-08-28       Impact factor: 53.440

Review 5.  Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?

Authors:  D A Sabbah; M G Brattain; H Zhong
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 6.  PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Authors:  Lise Willems; Jerome Tamburini; Nicolas Chapuis; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 7.  Phosphoinositide 3-kinase α inhibitors: a patent review.

Authors:  William A Denny
Journal:  Expert Opin Ther Pat       Date:  2013-03-14       Impact factor: 6.674

Review 8.  PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis.

Authors:  R C Castellino; C R Muh; D L Durden
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

9.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

10.  Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.

Authors:  W-C Hon; A Berndt; R L Williams
Journal:  Oncogene       Date:  2011-11-28       Impact factor: 9.867

View more
  18 in total

1.  Discovering new PI3Kα inhibitors with a strategy of combining ligand-based and structure-based virtual screening.

Authors:  Miao Yu; Qiong Gu; Jun Xu
Journal:  J Comput Aided Mol Des       Date:  2018-01-06       Impact factor: 3.686

2.  Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.

Authors:  Ignacia Echeverria; Yunlong Liu; Sandra B Gabelli; L Mario Amzel
Journal:  FEBS J       Date:  2015-07-24       Impact factor: 5.542

3.  Carbon dots enhance extracellular matrix secretion for dentin-pulp complex regeneration through PI3K/Akt/mTOR pathway-mediated activation of autophagy.

Authors:  Lili Liu; Xianjing Li; Wenhuan Bu; Nianqiang Jin; Yuan Meng; Yi Wang; Duan Wang; Xiaowei Xu; Ding Zhou; Hongchen Sun
Journal:  Mater Today Bio       Date:  2022-07-01

4.  A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.

Authors:  Danielle L Swaney; Dana J Ramms; Zhiyong Wang; Jisoo Park; Yusuke Goto; Margaret Soucheray; Neil Bhola; Kyumin Kim; Fan Zheng; Yan Zeng; Michael McGregor; Kari A Herrington; Rachel O'Keefe; Nan Jin; Nathan K VanLandingham; Helene Foussard; John Von Dollen; Mehdi Bouhaddou; David Jimenez-Morales; Kirsten Obernier; Jason F Kreisberg; Minkyu Kim; Daniel E Johnson; Natalia Jura; Jennifer R Grandis; J Silvio Gutkind; Trey Ideker; Nevan J Krogan
Journal:  Science       Date:  2021-10-01       Impact factor: 63.714

5.  ProSelection: A Novel Algorithm to Select Proper Protein Structure Subsets for in Silico Target Identification and Drug Discovery Research.

Authors:  Nanyi Wang; Lirong Wang; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2017-10-26       Impact factor: 4.956

6.  Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression.

Authors:  William Poole; Kalle Leinonen; Ilya Shmulevich; Theo A Knijnenburg; Brady Bernard
Journal:  PLoS Comput Biol       Date:  2017-02-07       Impact factor: 4.475

7.  Structural basis of nSH2 regulation and lipid binding in PI3Kα.

Authors:  Michelle S Miller; Oleg Schmidt-Kittler; David M Bolduc; Evan T Brower; Daniele Chaves-Moreira; Marc Allaire; Kenneth W Kinzler; Ian G Jennings; Philip E Thompson; Philip A Cole; L Mario Amzel; Bert Vogelstein; Sandra B Gabelli
Journal:  Oncotarget       Date:  2014-07-30

8.  Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold.

Authors:  Takako Takeda; Yanli Wang; Stephen H Bryant
Journal:  J Comput Aided Mol Des       Date:  2016-03-08       Impact factor: 3.686

9.  New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound.

Authors:  Xiuyan Yang; Xi Zhang; Min Huang; Kun Song; Xuefen Li; Meilang Huang; Linghua Meng; Jian Zhang
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

10.  Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.

Authors:  Hari Leontiadou; Ioannis Galdadas; Christina Athanasiou; Zoe Cournia
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.